Atara Biotherapeutics (ATRA) announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company’s previously announced $16 million offering that was announced on May 15, 2025. The offering closed on May 16, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRA:
- Atara Biotherapeutics Reports Strong Q1 2025 Results
- Atara Biotherapeutics Announces $16M Stock Offering
- Buy Rating for Atara Biotherapeutics: Strategic Focus and Financial Positioning Ahead of Key FDA Meeting
- Atara Biotherapeutics Appoints New Board Members Amid Restructuring
- Atara Biotherapeutics Announces Major Workforce Reduction